

Craig T Jordan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7597432/craig-t-jordan-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

243
papers

15,369
citations

57
h-index

122
g-index

256
ext. papers

17,853
ext. citations

7.1
avg, IF

6.51
L-index

#	Paper	IF	Citations
243	Cancer stem cells. <i>New England Journal of Medicine</i> , 2006 , 355, 1253-61	59.2	1256
242	BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. <i>Cell Stem Cell</i> , 2013 , 12, 329-41	18	740
241	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. <i>Blood</i> , 2001 , 98, 2301-7	2.2	631
240	The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. <i>Leukemia</i> , 2000 , 14, 1777-84	10.7	620
239	The increasing complexity of the cancer stem cell paradigm. <i>Science</i> , 2009 , 324, 1670-3	33.3	562
238	The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. <i>Blood</i> , 2005 , 105, 4163-9	2.2	544
237	A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. <i>Cell</i> , 1991 , 65, 1143-52	56.2	478
236	A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 9026-30	11.5	433
235	Clonal and systemic analysis of long-term hematopoiesis in the mouse. <i>Genes and Development</i> , 1990 , 4, 220-32	12.6	411
234	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018 , 562, 526-531	50.4	391
233	Preferential induction of apoptosis for primary human leukemic stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 16220-5	11.5	368
232	Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 2988-93	11.5	364
231	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. <i>Blood</i> , 2007 , 110, 4427-35	2.2	319
230	Leukemia stem cells and microenvironment: biology and therapeutic targeting. <i>Journal of Clinical Oncology</i> , 2011 , 29, 591-9	2.2	308
229	Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. <i>Nature Medicine</i> , 2018 , 24, 1859-1866	50.5	293
228	Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. <i>Cell Stem Cell</i> , 2016 , 19, 23-37	18	267
227	Regulation of myeloid leukaemia by the cell-fate determinant Musashi. <i>Nature</i> , 2010 , 466, 765-8	50.4	262

226	Cellular and developmental properties of fetal hematopoietic stem cells. <i>Cell</i> , 1990 , 61, 953-63	56.2	249
225	Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. <i>Cell Research</i> , 2015 , 25, 707-25	24.7	225
224	The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 11097-102	11.5	219
223	Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 16255-60	11.5	210
222	Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. <i>Cancer Cell</i> , 2018 , 34, 724-740.e4	24.3	204
221	The molecular basis of leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 80-97	3.1	180
220	Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. <i>International Journal of Cancer</i> , 2004 , 109, 507-15	7.5	163
219	Acute myeloid leukaemia. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16010	51.1	159
218	Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. <i>Blood</i> , 2008 , 111, 5654-62	2.2	157
217	Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. <i>Molecular and Cellular Biology</i> , 2003 , 23, 8992-9002	4.8	157
216	Therapeutic targeting of acute myeloid leukemia stem cells. <i>Blood</i> , 2017 , 129, 1627-1635	2.2	152
215	Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 4346-9	2.9	149
214	Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. <i>Blood</i> , 2012 , 119, 540-50	2.2	148
213	Cancer stem cells: controversial or just misunderstood?. <i>Cell Stem Cell</i> , 2009 , 4, 203-5	18	132
212	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. <i>Nature</i> , 2014 , 511, 90-3	50.4	129
211	Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. <i>Journal of Biological Chemistry</i> , 2013 , 288, 33542-33558	5.4	128
210	The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. <i>Blood</i> , 2008 , 111, 4681-9	2.2	128
209	Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. <i>Blood</i> , 2016 , 128, 1671-8	2.2	127

208	In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. <i>Cancer Cell</i> , 2013 , 24, 45-58	24.3	118
207	Leukemia stem cells in a genetically defined murine model of blast-crisis CML. <i>Blood</i> , 2007 , 110, 2578-85	2.2	117
206	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. <i>Cell Stem Cell</i> , 2018 , 23, 86-100.e6	18	116
205	Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. <i>Blood</i> , 2004 , 104, 687-95	2.2	116
204	Mechanisms controlling pathogenesis and survival of leukemic stem cells. <i>Oncogene</i> , 2004 , 23, 7178-87	9.2	105
203	Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 600-6	9.4	101
202	Unique molecular and cellular features of acute myelogenous leukemia stem cells. <i>Leukemia</i> , 2002 , 16, 559-62	10.7	97
201	Cancer stem cell biology: from leukemia to solid tumors. <i>Current Opinion in Cell Biology</i> , 2004 , 16, 708-12	9.6	96
200	Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). <i>Blood</i> , 2007 , 110, 4436-44	2.2	94
199	Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020 , 10, 536-551	24.4	93
198	Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. <i>PLoS ONE</i> , 2011 , 6, e23108	3.7	92
197	Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. <i>Bone</i> , 2006 , 39, 485-93	4.7	88
196	Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. <i>Haematologica</i> , 2014 , 99, 1277-84	6.6	83
195	The leukemic stem cell. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 13-8	4.2	82
194	Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization. <i>ACS Chemical Biology</i> , 2014 , 9, 164-73	4.9	79
193	Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. <i>Molecular and Cellular Biology</i> , 2005 , 25, 1100-12	4.8	72
192	Considerations for targeting malignant stem cells in leukemia. <i>Cancer Control</i> , 2004 , 11, 97-104	2.2	68
191	Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. <i>Blood</i> , 2010 , 116, 5983-90	2.2	66

190	In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. <i>Blood</i> , 2009 , 114, 4054-63	2.2	63
189	Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. <i>Blood</i> , 2019 , 134, 389-394	2.2	62
188	Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4079-4090	12.9	61
187	Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. <i>Blood Advances</i> , 2019 , 3, 2911-2919	7.8	60
186	The NF (Nuclear factor)- κ B inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2010 , 151, 70-83	4.5	55
185	Leukemia stem cells in 2010: current understanding and future directions. <i>Blood Reviews</i> , 2011 , 25, 75-81	11.1	55
184	Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. <i>Cancer Cell</i> , 2018 , 34, 659-673.e6	24.3	55
183	Noncanonical NF- κ B signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. <i>Stem Cells</i> , 2012 , 30, 709-18	5.8	52
182	Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. <i>Journal of Clinical Investigation</i> , 2014 , 124, 222-36	15.9	52
181	ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E6669-E6678	11.5	52
180	Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. <i>Cell Stem Cell</i> , 2012 , 11, 359-72	18	50
179	Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. <i>PLoS ONE</i> , 2009 , 4, e8115	3.7	50
178	Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. <i>Experimental Hematology</i> , 2002 , 30, 1162-9	3.1	49
177	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. <i>Blood</i> , 2001 , 97, 2177-9	2.2	47
176	Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1979-90	6.1	45
175	A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2058-2068	6.1	44
174	Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. <i>Cell Stem Cell</i> , 2020 , 27, 748-764.e4	18	43
173	Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. <i>Clinical Cancer Research</i> , 2015 , 21, 1360-72	12.9	42

172	The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. <i>Clinical Cancer Research</i> , 2008 , 14, 8102-11	12.9	42
171	Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. <i>Nature Communications</i> , 2018 , 9, 3694	17.4	41
170	The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. <i>Cell Reports</i> , 2019 , 27, 238-254.e6	10.6	37
169	Melampomagnolide B: a new antileukemic sesquiterpene. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 1515-9	3.4	37
168	Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. <i>Gene Therapy</i> , 1998 , 5, 465-72		37
167	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. <i>JCI Insight</i> , 2016 , 1, e85630	9.9	36
166	Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. <i>Oncotarget</i> , 2015 , 6, 14796-813	3.3	34
165	Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. <i>Oncotarget</i> , 2015 , 6, 6722-36	3.3	32
164	Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. <i>Experimental Hematology</i> , 2013 , 41, 799-807.e4	3.1	31
163	Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2008 , 19, 1759-64	10.3	31
162	The hematopoietic stem cell in myelodysplasia. <i>Stem Cells</i> , 2004 , 22, 590-9	5.8	31
161	MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. <i>JCI Insight</i> , 2018 , 3,	9.9	31
160	The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. <i>Advances in Experimental Medicine and Biology</i> , 2015 , 815, 349-59	3.6	30
159	SomVarIUS: somatic variant identification from unpaired tissue samples. <i>Bioinformatics</i> , 2016 , 32, 808-13	7.2	29
158	Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. <i>Blood</i> , 2008 , 111, 1644-53	2.2	29
157	A new type of stochastic dependence revealed in gene expression data. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2006 , 5, Article7	1.2	29
156	NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. <i>Biology of Blood and Marrow Transplantation</i> , 2010 ,	4.7	28
155	Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression. <i>Cell Research</i> , 2008 , 18, 281-9	24.7	26

154	Searching for leukemia stem cells--not yet the end of the road?. <i>Cancer Cell</i> , 2006 , 10, 253-4	24.3	26
153	Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. <i>Leukemia</i> , 1999 , 13, 1608-16	10.7	26
152	MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1438-50	15.9	26
151	Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. <i>Nature Cancer</i> , 2020 , 1, 1176-1187	15.4	26
150	Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 3876-3886	3.4	24
149	Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. <i>Journal of Biological Chemistry</i> , 2016 , 291, 21984-22000	5.4	24
148	Selenium suppresses leukemia through the action of endogenous eicosanoids. <i>Cancer Research</i> , 2014 , 74, 3890-901	10.1	23
147	Micelle Delivery of Parthenolide to Acute Myeloid Leukemia Cells. <i>Cellular and Molecular Bioengineering</i> , 2015 , 8, 455-470	3.9	22
146	A phase I study of decitabine and rapamycin in relapsed/refractory AML. <i>Leukemia Research</i> , 2013 , 37, 1622-7	2.7	21
145	Recent progress in identifying genes regulating hematopoietic stem cell function and fate. <i>Current Opinion in Cell Biology</i> , 1998 , 10, 716-20	9	20
144	Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. <i>Haematologica</i> , 2019 , 104, e388-e392	6.6	19
143	Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. <i>Leukemia</i> , 2014 , 28, 1960-8	10.7	19
142	Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 8896-906	8.3	18
141	MMB triazole analogs are potent NF- κ B inhibitors and anti-cancer agents against both hematological and solid tumor cells. <i>European Journal of Medicinal Chemistry</i> , 2018 , 157, 562-581	6.8	18
140	Targeting myeloid leukemia stem cells. <i>Science Translational Medicine</i> , 2010 , 2, 31ps21	17.5	18
139	Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. <i>Leukemia</i> , 2009 , 23, 1587-97	9.7	18
138	The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. <i>Blood</i> , 2008 , 112, 4184-92	2.2	18
137	A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2013 , 37, 1502-8	2.7	16

136	Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes. <i>Human Gene Therapy</i> , 1999 , 10, 1875-84	4.8	16
135	PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	16
134	Aldehyde dehydrogenases in acute myeloid leukemia. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1310, 58-68	6.5	15
133	Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. <i>Haematologica</i> , 2020 , 105, 585-597	6.6	15
132	Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. <i>European Journal of Medicinal Chemistry</i> , 2017 , 136, 393-405	6.8	14
131	Protein kinase C-associated kinase regulates NF- κ B activation through inducing IKK activation. <i>International Journal of Oncology</i> , 2014 , 45, 1707-14	4.4	14
130	How close are we to targeting the leukemia stem cell?. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 415-8	4.2	14
129	Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. <i>Cell Stem Cell</i> , 2021 , 28, 378-393	18	14
128	Succinamide derivatives of melampomagnolide B and their anti-cancer activities. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 3694-3705	3.4	13
127	CD123 CAR T cells for the treatment of myelodysplastic syndrome. <i>Experimental Hematology</i> , 2019 , 74, 52-63.e3	3.1	13
126	Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells. <i>PLoS ONE</i> , 2014 , 9, e85702	3.7	13
125	Venetoclax and Azacitidine Compared to Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia. <i>Blood Advances</i> , 2021 ,	7.8	12
124	Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. <i>Leukemia and Lymphoma</i> , 2016 , 57, 927-34	1.9	11
123	Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. <i>Haematologica</i> , 2017 , 102, 1054-1065	6.6	10
122	Leukemia stemness signatures step toward the clinic. <i>Cell Stem Cell</i> , 2011 , 9, 185-6	18	10
121	Can we finally target the leukemic stem cells?. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 615-20	4.2	10
120	PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia. <i>Blood</i> , 2018 , 132, 909-909	2.2	10
119	The PKC β Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells.. <i>Blood</i> , 2005 , 106, 1483-1483	2.2	9

118	Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?. <i>Current Opinion in Hematology</i> , 2019 , 26, 71-76	3.3	8
117	Can we selectively target AML stem cells?. <i>Best Practice and Research in Clinical Haematology</i> , 2019 , 32, 101100	4.2	8
116	Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. <i>Cancer Cell</i> , 2009 , 15, 252-4	24.3	8
115	Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 1235-1241	3.4	7
114	Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 4879-83	2.9	7
113	Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. <i>Cancer Investigation</i> , 2011 , 29, 439-50	2.1	7
112	The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. <i>Cancer Discovery</i> , 2021 , 11, 500-519	24.4	7
111	Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. <i>Oncogene</i> , 2013 , 32, 3809-18	9.2	6
110	Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse. <i>Blood</i> , 2020 , 136, 11-12	2.2	6
109	Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	6
108	Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 5855-5860	3.4	6
107	Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020 , 197, 112316	6.8	6
106	High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 622-30	4.7	5
105	Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy. <i>Blood</i> , 2020 , 136, 24-24	2.2	5
104	Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization. <i>ACS Central Science</i> , 2021 , 7, 841-857	16.8	5
103	Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. <i>Blood Advances</i> , 2020 , 4, 1628-1639	7.8	5
102	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. <i>Leukemia Research</i> , 2019 , 81, 43-49	2.7	4
101	A test of homogeneity for age-dependent branching processes with immigration. <i>Electronic Journal of Statistics</i> , 2015 , 9, 898-925	1.2	4

100	Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. <i>Frontiers in Pharmacology</i> , 2013 , 4, 9	5.6	4
99	A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. <i>Prostate</i> , 2010 , 70, 1379-87	4.2	4
98	Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant. <i>Blood</i> , 2018 , 132, 2138-2138	2.2	4
97	Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine. <i>Blood</i> , 2019 , 134, 1272-1272	2.2	4
96	The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1466-1473	1.9	4
95	The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation. <i>Blood</i> , 2021 ,	2.2	4
94	Clinical infection control in gene therapy: a multidisciplinary conference. <i>Infection Control and Hospital Epidemiology</i> , 2000 , 21, 659-73	2	3
93	Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features. <i>Blood</i> , 2020 , 136, 9-9	2.2	3
92	A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells. <i>Blood</i> , 2006 , 108, 237-237	2.2	3
91	Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting. <i>STAR Protocols</i> , 2021 , 2, 100248	1.4	3
90	The potential of targeting malignant stem cells as a treatment for leukemia. <i>Future Oncology</i> , 2005 , 1, 205-7	3.6	2
89	The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells. <i>Current Gene Therapy</i> , 2001 , 1, 257-65	4.3	2
88	Selective Induction of Apoptosis in Acute Myelogenous Leukemia Stem Cells by the Novel Agent Parthenolide. <i>Blood</i> , 2004 , 104, 2542-2542	2.2	2
87	Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. <i>Blood</i> , 2012 , 120, 206-206	2.2	2
86	Cellular Iron Status Is Associated with Better Survival and Increased Chemotherapy Sensitivity in AML. <i>Blood</i> , 2015 , 126, 4975-4975	2.2	2
85	CD46 Antibody Drug Conjugate Impedes Myeloma Engraftment in Patient-Derived Xenografts. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e151	2	2
84	Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 819-830	12.9	2
83	Antitumor properties of novel sesquiterpene lactone analogs as NFB inhibitors that bind to the IKK α ubiquitin-like domain (ULD). <i>European Journal of Medicinal Chemistry</i> , 2021 , 224, 113675	6.8	2

82	The gold standard improves: a better assay for HSCs. <i>Blood</i> , 2005 , 106, 1141-1142	2.2	1
81	ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. <i>JCI Insight</i> , 2020 , 5,	9.9	1
80	A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients. <i>Blood</i> , 2018 , 132, 3203-3203	2.2	1
79	Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy. <i>Blood</i> , 2019 , 134, 2638-2638	2.2	1
78	Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy. <i>Blood</i> , 2019 , 134, 185-185	2.2	1
77	Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death.. <i>Blood</i> , 2006 , 108, 2592-2592	2.2	1
76	Prostaglandin E2 (PGE2) Regulates Osteoblastic Jagged1 and Expands Primitive Hematopoietic Cells In Vivo.. <i>Blood</i> , 2006 , 108, 89-89	2.2	1
75	Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL).. <i>Blood</i> , 2007 , 110, 2325-2325	2.2	1
74	Reciprocal Synergistic Interactions of Leukemic Cells with Osteoclast Progenitors in the Bone Microenvironment. <i>Blood</i> , 2008 , 112, 322-322	2.2	1
73	Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009 , 114, 2070-2070	2.2	1
72	Analysis of the Anti-Leukemia Mechanism of Parthenolide.. <i>Blood</i> , 2009 , 114, 2734-2734	2.2	1
71	Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide.. <i>Blood</i> , 2009 , 114, 388-388	2.2	1
70	Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance. <i>Blood</i> , 2010 , 116, 4192-4192	2.2	1
69	A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. <i>Blood</i> , 2015 , 126, 4266-4266	2.2	1
68	Adipose Tissue Functions As a Reservoir for Leukemia Stem Cells and Confers Chemo-Resistance. <i>Blood</i> , 2015 , 126, 845-845	2.2	1
67	Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia. <i>Blood</i> , 2016 , 128, 1703-1703	2.2	1
66	ETV6 Regulates Pax5 Expression in Early B Cell Development. <i>Blood</i> , 2016 , 128, 2655-2655	2.2	1
65	Human Cytomegalovirus Infection of Primitive Hematopoietic Progenitor Cells: A Model for Latency.. <i>Blood</i> , 2004 , 104, 1703-1703	2.2	1

64	Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1. <i>Blood</i> , 2018 , 132, 432-432	2.2	1
63	Leukemia Cells Resident in Adipose Tissue Display a Pro-Inflammatory Phenotype and Induce Lipolysis and Atrophy of Adipose Tissue. <i>Blood</i> , 2015 , 126, 2765-2765	2.2	1
62	Rational Combinations Including a Novel Syk Inhibitor, Fostamatinib Disodium (FosD) in Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 283-283	2.2	1
61	Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression. <i>Blood</i> , 2013 , 122, 883-883	2.2	1
60	Delivery of a model lipophilic membrane cargo to bone marrow via cell-derived microparticles. <i>Journal of Controlled Release</i> , 2020 , 326, 324-334	11.7	1
59	MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. <i>Journal of Leukocyte Biology</i> , 2021 , 110, 197-205	6.5	0
58	Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality. <i>Blood</i> , 2018 , 132, 2573-2573	2.2	0
57	Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. <i>Blood</i> , 2021 , 138, 3957-3957	2.2	0
56	Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells. <i>Blood</i> , 2021 , 138, 1511-1511	2.2	0
55	Mechanisms Controlling Selective Death of Leukemia Stem Cells in Response to Parthenolide.. <i>Blood</i> , 2005 , 106, 467-467	2.2	0
54	A Search of Public Gene Expression Microarray Data Identifies Novel Agents That Selectively Eradicate AML Stem Cells.. <i>Blood</i> , 2007 , 110, 776-776	2.2	0
53	Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance. <i>Blood</i> , 2014 , 124, 2238-2238	2.2	0
52	MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 4044-4044	2.2	0
51	Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009 , 114, 3774-3774	2.2	0
50	Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity.. <i>Blood</i> , 2009 , 114, 3764-3764	2.2	0
49	Troglitazone and Prochloroperazine Repositioned As An Anti-Leukemia Stem Cell Drug Combination Using Chemical Genomics-Based Prediction. <i>Blood</i> , 2011 , 118, 1885-1885	2.2	0
48	Reactive Oxygen Species (ROS) Levels Define Functional Heterogeneity in Human Leukemia Stem Cells and Represent a Critical Parameter for Therapeutic Targeting. <i>Blood</i> , 2011 , 118, 639-639	2.2	0
47	Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies. <i>Blood</i> , 2021 , 138, 2612-2612	2.2	

- 46 Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia. *Blood*, **2021**, 138, 630-630 2.2
- 45 Characterization and Functional Analysis of a Murine Model for Chronic Myeloid Leukemia Stem Cells.. *Blood*, **2004**, 104, 4476-4476 2.2
- 44 Osteoblastic Cells and the Hematopoietic Microenvironment: The Notch ligand Jagged1 Is Increased in Osteoblastic Stromal Cells by Parathyroid Hormone (PTH)Treatment.. *Blood*, **2004**, 104, 1284-1284 2.2
- 43 Modeling the Origins of Lymphoid Blast Crisis Via Expression of BCR/ABL in Hematopoietic Cells Mutated at the INK4a/ARF Locus.. *Blood*, **2005**, 106, 464-464 2.2
- 42 Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects.. *Blood*, **2006**, 108, 3247-3247 2.2
- 41 In Vivo Analyses of Leukemia Stem Cells in Genetically Defined Murine Models of Chronic and Blast Crisis CML.. *Blood*, **2006**, 108, 236-236 2.2
- 40 Rapid Loss of Membrane Integrity and Irreversible Commitment to Cell Death of Primary AML Stem Cells: A Novel Activity for 4-benzyl, 2-methyl,1,2,4-Thiadiazolidine,3,5 Dione (TDZD-8).. *Blood*, **2006**, 108, 2535-2535 2.2
- 39 In Vivo Treatment with Prostaglandin E2 (PGE2) Selectively Expands Short-Term Hematopoietic Stem Cells.. *Blood*, **2007**, 110, 1254-1254 2.2
- 38 Cysteine and Cystine Depletion Targets Leukemia Stem Cells. *Blood*, **2018**, 132, 431-431 2.2
- 37 Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism. *Blood*, **2018**, 132, 429-429 2.2
- 36 PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71. *Blood*, **2019**, 134, 3935-3935 2.2
- 35 STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells. *Blood*, **2019**, 134, 1275-1275 2.2
- 34 Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples. *Blood*, **2019**, 134, 4404-4404 2.2
- 33 PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation. *Blood*, **2019**, 134, 822-822 2.2
- 32 Targeting acute myelogenous leukemia stem cells93-108
- 31 Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin. *Blood*, **2014**, 124, 838-838 2.2
- 30 Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function. *Blood*, **2015**, 126, 842-842 2.2
- 29 Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia. *Blood*, **2015**, 126, 2428-2428 2.2

- 28 A Novel Isoflavone, ME-344, Targets the Cytoskeleton in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3682-3682
- 27 Characterization and Targeting of Myelodysplastic Syndrome Stem Cells. *Blood*, **2015**, 126, 4104-4104 2.2
- 26 IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience. *Blood*, **2015**, 126, 1443-1443 2.2
- 25 The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis. *Blood*, **2016**, 128, 1079-1079 2.2
- 24 Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention. *Blood*, **2016**, 128, 4316-4316 2.2
- 23 Development of Anti-IL-1R3 Monoclonal Antibodies for Treating Cancer and IL-1 Family-Mediated Inflammation. *Blood*, **2016**, 128, 5224-5224 2.2
- 22 Adipose Tissue-Derived IGFBP1 Facilitates Progression of Leukemia. *Blood*, **2016**, 128, 3058-3058 2.2
- 21 Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes. *Blood*, **2016**, 128, 3054-3054 2.2
- 20 A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML). *Blood*, **2008**, 112, 2953-2953 2.2
- 19 Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents.. *Blood*, **2008**, 112, 1595-1595 2.2
- 18 CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML. *Blood*, **2008**, 112, 4003-4003 2.2
- 17 Genes Dysregulated in a Murine Model of Leukemogenesis Comprise a Signature for Identification of Therapeutics in Humans.. *Blood*, **2008**, 112, 3349-3349 2.2
- 16 Clonally Related B-NHL Populations and Cell Lines Harbor Subsets with Significant Phenotypic and Functional Heterogeneity.. *Blood*, **2009**, 114, 1699-1699 2.2
- 15 Synergistically Regulated Genes and Pathways in Leukemias Induced by Co-Expression of BCR-ABL and Nup98-HoxA9.. *Blood*, **2009**, 114, 3473-3473 2.2
- 14 Heterogeneity in Phenotype, Functional Capacity, and Drug Sensitivity for Pediatric Acute Leukemia.. *Blood*, **2009**, 114, 2654-2654 2.2
- 13 Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation.. *Blood*, **2009**, 114, 3966-3966 2.2
- 12 Isolation and Functional Characterization of a Novel Oxidative State Low Leukemic Population with Stem Cell Properties and Potential Resistance to Chemotherapy In Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1580-1580 2.2
- 11 Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104. *Blood*, **2010**, 116, 868-868 2.2

10	Microenvironmental Changes In An In Vivo Model of Myeloid Leukemia Negatively Regulate Osteoblastic Cells.. <i>Blood</i> , 2010 , 116, 1219-1219	2.2
9	Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells,. <i>Blood</i> , 2011 , 118, 3506-3506	2.2
8	Molecular Mechanisms of Parthenolide-Mediated Pro-Apoptotic Activity in Acute Myeloid Leukemia Cells. <i>Blood</i> , 2011 , 118, 2463-2463	2.2
7	Oncogene Cooperativity Analysis Reveals a Novel Set of Genes That Regulate the In Vivo Growth and Survival of Leukemia Stem Cells. <i>Blood</i> , 2011 , 118, 553-553	2.2
6	High Throughput Screening Reveals Unique Sensitivity of CD34+CD38- AML Cells to Isotretinoin and Tretinoin. <i>Blood</i> , 2011 , 118, 1430-1430	2.2
5	In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. <i>Blood</i> , 2011 , 118, 758-758	2.2
4	Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia. <i>Blood</i> , 2012 , 120, 3549-3549	2.2
3	Rocaglamide Selectively Eradicates Human Leukemia Stem Cells and Synergizes with Multiple Agents to Target AML Cells. <i>Blood</i> , 2012 , 120, 1338-1338	2.2
2	ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May Be Exploited to Treat AML. <i>Blood</i> , 2013 , 122, 2893-2893	2.2
1	309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations. <i>Journal of Clinical and Translational Science</i> , 2022 , 6, 54-54	0.4